Levodopa/carbidopa

Levodopa/carbidopa Reactions 1704, p225 - 2 Jun 2018 Psychosis: case report A 73-year-old woman developed psychosis during treatment with levodopa/carbidopa [route and dosage not stated and time to reaction onset not clearly stated]. The woman had a two year history of parkinsonism and dementia which was treated with levodopa/carbidopa. She was admitted with catatonia/unresponsiveness. A month before admission, she was using a walker to get food in a buffet line. A few days later, she started experiencing hallucinations and depression. She was treated with citalopram and quetiapine. On next morning, she woke up but was unable to move. She was transferred to the psychiatric unit and was discharged to a skilled nursing facility on primavanserin and olanzapine treatment after 8 days. Despite this, she continued to experience "unresponsive" or "trance- like" episodes every other day. Extensive workup including autoimmune studies revealed presence of anti-TPO was positive. She underwent IV immune globulin treatment for concerns of Hashimoto’s encephalopathy, but without any improvement. Stopping the rivastigmine and antipsychotics improved cognition. The woman’s levodopa/carbidopa treatment was restarted as the cessation worsened parkinsonism features. Author comment: "The most important cause of psychosis in [Parkinson’s disease] is probably the dopamine agonists used to treat it." Ahmad S. Parkinsons disease with psychosis Ahmad, Sobia MD Geriatric Medicine, Summa Health Journal of the American Geriatrics Society 66 (Suppl. 2): S190 abstr. C50, Apr 2018. Available from: URL: http://doi.org/10.1111/jgs.15376 [abstract] - USA 803323529 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Levodopa/carbidopa

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/levodopa-carbidopa-nvF0mxn4xk
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46868-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p225 - 2 Jun 2018 Psychosis: case report A 73-year-old woman developed psychosis during treatment with levodopa/carbidopa [route and dosage not stated and time to reaction onset not clearly stated]. The woman had a two year history of parkinsonism and dementia which was treated with levodopa/carbidopa. She was admitted with catatonia/unresponsiveness. A month before admission, she was using a walker to get food in a buffet line. A few days later, she started experiencing hallucinations and depression. She was treated with citalopram and quetiapine. On next morning, she woke up but was unable to move. She was transferred to the psychiatric unit and was discharged to a skilled nursing facility on primavanserin and olanzapine treatment after 8 days. Despite this, she continued to experience "unresponsive" or "trance- like" episodes every other day. Extensive workup including autoimmune studies revealed presence of anti-TPO was positive. She underwent IV immune globulin treatment for concerns of Hashimoto’s encephalopathy, but without any improvement. Stopping the rivastigmine and antipsychotics improved cognition. The woman’s levodopa/carbidopa treatment was restarted as the cessation worsened parkinsonism features. Author comment: "The most important cause of psychosis in [Parkinson’s disease] is probably the dopamine agonists used to treat it." Ahmad S. Parkinsons disease with psychosis Ahmad, Sobia MD Geriatric Medicine, Summa Health Journal of the American Geriatrics Society 66 (Suppl. 2): S190 abstr. C50, Apr 2018. Available from: URL: http://doi.org/10.1111/jgs.15376 [abstract] - USA 803323529 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off